Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.
On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.
2022-05-25 | Sale | Royston Aaron | 702,737 3.1622% | $4.12 | $2.9M | -69.80% | ||
2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 187,500 22.5074% | $16.00 | $3M | -56.00% | ||
2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 625,000 75.0247% | $16.00 | $10M | -56.00% | ||
2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 312,500 37.5123% | $16.00 | $5M | -56.00% | ||
2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 250,000 30.0099% | $16.00 | $4M | -56.00% | ||
2021-06-29 | Cormorant Asset Management, LP | 250,000 30.0099% | $16.00 | $4M | -56.00% |
Aisling Capital IV, LP | 10 percent owner | 2834910 4.7874% | $1.37M | 1 | 0 | <0.0001% |
venBio Global Strategic Fund III, L.P. | 10 percent owner | 2608167 4.4045% | $1.26M | 1 | 0 | <0.0001% |
Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2370142 4.0025% | $1.14M | 1 | 0 | <0.0001% |
Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2307642 3.897% | $1.11M | 1 | 0 | <0.0001% |
Cormorant Asset Management, LP | 2233168 3.7712% | $1.08M | 1 | 0 | <0.0001% |
$14,315,062 | 61 | -6.21% | $30.86M | |
$53,490,060 | 55 | 19.35% | $32.57M | |
$94,084,626 | 29 | -21.08% | $27.92M | |
$1,295,471 | 17 | 21.79% | $24.68M | |
$17,594,514 | 16 | -20.37% | $32.66M |
Increased Positions | 39 | +58.21% | 2M | +4.68% |
Decreased Positions | 24 | -35.82% | 9M | -18.78% |
New Positions | 14 | New | 1M | New |
Sold Out Positions | 11 | Sold Out | 4M | Sold Out |
Total Postitions | 82 | +22.39% | 40M | -14.09% |
Frazier Life Sciences Management, L.P. | $3,195.00 | 10.16% | 5.99M | 0 | 0% | 2024-12-31 |
Tang Capital Management Llc | $2,537.00 | 8.07% | 4.76M | 0 | 0% | 2024-12-31 |
Farallon Capital Management Llc | $1,880.00 | 5.98% | 3.53M | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $1,686.00 | 5.36% | 3.16M | +258,009 | +8.88% | 2024-12-31 |
Bvf Inc/Il | $1,581.00 | 5.03% | 2.97M | 0 | 0% | 2024-12-31 |
Aisling Capital Management Lp | $1,511.00 | 4.81% | 2.83M | 0 | 0% | 2024-12-31 |
Vanguard Group Inc | $1,391.00 | 4.42% | 2.61M | -461,535 | -15.03% | 2024-12-31 |
Goldman Sachs Group Inc | $880.00 | 2.8% | 1.65M | -2M | -58.59% | 2024-12-31 |
Renaissance Technologies Llc | $855.00 | 2.72% | 1.6M | -182,673 | -10.23% | 2024-12-31 |
Geode Capital Management, Llc | $617.00 | 1.96% | 1.16M | +47,487 | +4.28% | 2024-12-31 |